RxDoctor Payments Data

Veronica Marcantoni-Nevers, MD

Internal Medicine · Dublin, OHNPI 1992097182

Payments from drug & device makers

$535in general payments, 2019–2025

Across 28 payments — averaging $19.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$97
  • Corcept Therapeutics$59
  • AstraZeneca$49
  • Astellas Pharma US Inc$42
  • Xeris Pharmaceuticals, Inc.$39
  • Lilly USA, LLC$34
  • plus $216 from 9 others

What the payments were for

  • Food & beverage$535100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$535 in reported general payments places this provider in the 65th percentile of 4,428 internal medicine providers in Ohio.

See all internal medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$57,674
Medicare patients
119
Services billed
1,915

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide89$128,799
OzempicSemaglutide39$54,539
EliquisApixaban38$43,815
Synjardy XrEmpagliflozin/Metformin Hcl20$25,982
JardianceEmpagliflozin16$23,233
XareltoRivaroxaban17$20,763
Breo ElliptaFluticasone/Vilanterol17$14,601
JanuviaSitagliptin Phosphate14$12,378
ShingrixVaricella-Zoster Ge/As01b/Pf12$2,660
Lantus SolostarInsulin Glargine,hum.Rec.Anlog17$2,013
Rosuvastatin Calcium157$1,997
Atorvastatin Calcium204$1,973
Adacel TdapDiph,pertuss(Acell),tet Vac/Pf26$1,874
Metoprolol Succinate98$1,262
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide20$1,241

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$34$128,79989 claims
Novo NordiskOzempic$97$54,53939 claims
PfizerEliquis$25$43,81538 claims
Johnson & JohnsonXarelto$16$20,76317 claims
GSKBreo Ellipta, Shingrix$29$17,26029 claims
AbbVieSynthroid$32$1,11713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 4,428 internal medicine providers in Ohio.

Other internal medicine in Dublin

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →